Description

Nelova 200 mg contains Nilotinib, a second-generation BCR-ABL tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia. It is designed to specifically target leukemia cells with the Philadelphia chromosome abnormality.

🔬 Mechanism of Action

Nilotinib selectively inhibits the BCR-ABL tyrosine kinase, the abnormal protein responsible for uncontrolled proliferation of leukemic cells in CML. By blocking this enzyme, Nelova 200 mg:

• Prevents leukemia cell growth
• Promotes apoptosis (programmed cell death)
• Helps control disease progression

This targeted mechanism makes it effective for patients who are newly diagnosed or resistant to certain other therapies.

💊 Indications

Nelova 200 mg is indicated for:

• Newly diagnosed Philadelphia chromosome–positive Chronic Myeloid Leukemia (Ph+ CML) in chronic phase
• Chronic or accelerated phase CML in patients resistant or intolerant to prior therapy such as imatinib

📌 Key Features of Nelova 200 mg

• Strength: 200 mg
• Dosage Form: Oral capsule
• Therapeutic Class: BCR-ABL Tyrosine Kinase Inhibitor
• Administration: Usually taken twice daily on an empty stomach as prescribed
• Monitoring: Regular blood counts, liver function tests, and ECG monitoring recommended

⚕️ Benefits of Nilotinib

• Highly targeted therapy for CML
• Effective in patients resistant to earlier treatments
• Helps achieve and maintain molecular remission
• Oral therapy for convenient long-term management

⚠️ Precautions

• Risk of QT interval prolongation; ECG monitoring required
• Possible side effects include rash, headache, nausea, and fatigue
• Risk of liver dysfunction and pancreatitis
• Drug interactions may occur
• Use strictly under hematologist or oncologist supervision

Nelova 200 mg (Nilotinib Capsules) provides an advanced targeted treatment option for chronic myeloid leukemia, helping control disease progression and improve long-term outcomes when used under specialized medical care.